Last 12 months
Inside the activity.
3 purchase rows · 2 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 0 |
| Dec 2025 | 0 | 0 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 0 |
| Mar 2026 | 0 | 0 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 0 |
| Jun 2026 | 0 | 1 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 3 | 1 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 28, 2020 Filed Mar 3, 2020 17:54 UTC |
JOHNSON RADY AExecutive Vice President
|
Tax withholdingCommon Stock | 2,627 | $33.42 | $87,794.34 |
DisclosureSEC source: 0001225208-20-004023 · doc4.xml · nonDerivative · entry 2 JOHNSON RADY A · CIK 0001594762 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 85,329 F2 · shares: The reported transaction constitutes the withholding of shares to satisfy tax obligations in connection with earn-out of stock appreciation rights. Read SEC document |
| February 28, 2020 Filed Mar 3, 2020 17:54 UTC |
JOHNSON RADY AExecutive Vice President
|
Exercise / conversionCommon Stock | 15,996 | $27.37 | $437,810.52 |
DisclosureSEC source: 0001225208-20-004023 · doc4.xml · nonDerivative · entry 1 JOHNSON RADY A · CIK 0001594762 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,956 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The reported transaction constitutes the earn-out of stock appreciation rights (including dividend equivalents thereon). Read SEC document |
| February 28, 2020 Filed Mar 3, 2020 17:54 UTC |
LANKLER DOUGLAS MExecutive Vice President
|
Exercise / conversionStock Appreciation Rights · Derivative | 38,848 | $0.00 Strike: $27.37 | $0.00 |
DisclosureSEC source: 0001225208-20-004024 · doc4.xml · derivative · entry 5 LANKLER DOUGLAS M · CIK 0001488270 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 38,848 shares Expires 2020-02-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 28, 2020 Filed Mar 3, 2020 17:54 UTC |
LANKLER DOUGLAS MExecutive Vice President
|
Tax withholdingCommon Stock | 20,069 | $36.45 | $731,515.05 |
DisclosureSEC source: 0001225208-20-004024 · doc4.xml · nonDerivative · entry 3 LANKLER DOUGLAS M · CIK 0001488270 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 143,276 F3 · shares: The reported transaction constitutes the withholding of shares to cover payment of exercise price in connection with earn-out of stock appreciation rights (including dividend equivalents thereon). F4 · price: Under the terms of the settlement of the stock appreciation rights the 20-day average of the closing prices of Pfizer common stock ending on the settlement date is used. Read SEC document |
| February 28, 2020 Filed Mar 3, 2020 17:54 UTC |
LANKLER DOUGLAS MExecutive Vice President
|
Tax withholdingCommon Stock | 9,197 | $33.42 | $307,363.74 |
DisclosureSEC source: 0001225208-20-004024 · doc4.xml · nonDerivative · entry 2 LANKLER DOUGLAS M · CIK 0001488270 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 163,345 F2 · shares: The reported transaction constitutes the withholding of shares to satisfy tax obligations in connection with earn-out of stock appreciation rights. Read SEC document |
| February 28, 2020 Filed Mar 3, 2020 17:54 UTC |
LANKLER DOUGLAS MExecutive Vice President
|
Exercise / conversionCommon Stock | 38,848 | $27.37 | $1,063,269.76 |
DisclosureSEC source: 0001225208-20-004024 · doc4.xml · nonDerivative · entry 1 LANKLER DOUGLAS M · CIK 0001488270 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 172,542 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The reported transaction constitutes the earn-out of stock appreciation rights (including dividend equivalents thereon). Read SEC document |
| February 28, 2020 Filed Mar 3, 2020 17:54 UTC |
MACKENZIE ALEXANDER RExecutive Vice President
|
Exercise / conversionStock Appreciation Rights · Derivative | 37,934 | $0.00 Strike: $27.37 | $0.00 |
DisclosureSEC source: 0001225208-20-004025 · doc4.xml · derivative · entry 5 MACKENZIE ALEXANDER R · CIK 0001678459 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 37,934 shares Expires 2020-02-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 28, 2020 Filed Mar 3, 2020 17:54 UTC |
MACKENZIE ALEXANDER RExecutive Vice President
|
Tax withholdingCommon Stock | 19,597 | $36.45 | $714,310.65 |
DisclosureSEC source: 0001225208-20-004025 · doc4.xml · nonDerivative · entry 3 MACKENZIE ALEXANDER R · CIK 0001678459 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 110,899 F3 · shares: The reported transaction constitutes the withholding of shares to cover payment of exercise price in connection with earn-out of stock appreciation rights (including dividend equivalents thereon). F4 · price: Under the terms of the settlement of the stock appreciation rights the 20-day average of the closing prices of Pfizer common stock ending on the settlement date is used. Read SEC document |
| February 28, 2020 Filed Mar 3, 2020 17:54 UTC |
MACKENZIE ALEXANDER RExecutive Vice President
|
Tax withholdingCommon Stock | 9,760 | $33.42 | $326,179.20 |
DisclosureSEC source: 0001225208-20-004025 · doc4.xml · nonDerivative · entry 2 MACKENZIE ALEXANDER R · CIK 0001678459 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 130,496 F2 · shares: The reported transaction constitutes the withholding of shares to satisfy tax obligations in connection with earn-out of stock appreciation rights. Read SEC document |
| February 28, 2020 Filed Mar 3, 2020 17:54 UTC |
MACKENZIE ALEXANDER RExecutive Vice President
|
Exercise / conversionCommon Stock | 37,934 | $27.37 | $1,038,253.58 |
DisclosureSEC source: 0001225208-20-004025 · doc4.xml · nonDerivative · entry 1 MACKENZIE ALEXANDER R · CIK 0001678459 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 140,256 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The reported transaction constitutes the earn-out of stock appreciation rights (including dividend equivalents thereon). Read SEC document |
| February 28, 2020 Filed Mar 3, 2020 17:54 UTC |
ROGERS DAWNExecutive Vice President
|
Exercise / conversionStock Appreciation Rights · Derivative | 17,824 | $0.00 Strike: $27.37 | $0.00 |
DisclosureSEC source: 0001225208-20-004026 · doc4.xml · derivative · entry 5 ROGERS DAWN · CIK 0001742308 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 17,824 shares Expires 2020-02-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 28, 2020 Filed Mar 3, 2020 17:54 UTC |
ROGERS DAWNExecutive Vice President
|
Tax withholdingCommon Stock | 9,208 | $36.45 | $335,631.60 |
DisclosureSEC source: 0001225208-20-004026 · doc4.xml · nonDerivative · entry 3 ROGERS DAWN · CIK 0001742308 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,823 F3 · shares: The reported transaction constitutes the withholding of shares to cover payment of exercise price in connection with earn-out of stock appreciation rights (including dividend equivalents thereon). F4 · price: Under the terms of the settlement of the stock appreciation rights the 20-day average of the closing prices of Pfizer common stock ending on the settlement date is used. Read SEC document |
| February 28, 2020 Filed Mar 3, 2020 17:54 UTC |
ROGERS DAWNExecutive Vice President
|
Tax withholdingCommon Stock | 3,014 | $33.42 | $100,727.88 |
DisclosureSEC source: 0001225208-20-004026 · doc4.xml · nonDerivative · entry 2 ROGERS DAWN · CIK 0001742308 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,031 F2 · shares: The reported transaction constitutes the withholding of shares to satisfy tax obligations in connection with earn-out of stock appreciation rights. Read SEC document |
| February 28, 2020 Filed Mar 3, 2020 17:54 UTC |
ROGERS DAWNExecutive Vice President
|
Exercise / conversionCommon Stock | 17,824 | $27.37 | $487,842.88 |
DisclosureSEC source: 0001225208-20-004026 · doc4.xml · nonDerivative · entry 1 ROGERS DAWN · CIK 0001742308 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,045 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The reported transaction constitutes the earn-out of stock appreciation rights (including dividend equivalents thereon). Read SEC document |
| February 28, 2020 Filed Mar 3, 2020 17:55 UTC |
YOUNG JOHN DGroup President
|
Exercise / conversionStock Appreciation Rights · Derivative | 100,548 | $0.00 Strike: $27.37 | $0.00 |
DisclosureSEC source: 0001225208-20-004028 · doc4.xml · derivative · entry 6 YOUNG JOHN D · CIK 0001551792 · Group President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 100,548 shares Expires 2020-02-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 28, 2020 Filed Mar 3, 2020 17:55 UTC |
YOUNG JOHN DGroup President
|
Tax withholdingCommon Stock | 51,943 | $36.45 | $1,893,322.35 |
DisclosureSEC source: 0001225208-20-004028 · doc4.xml · nonDerivative · entry 3 YOUNG JOHN D · CIK 0001551792 · Group President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 428,682 F3 · shares: The reported transaction constitutes the withholding of shares to cover payment of exercise price in connection with earn-out of stock appreciation rights (including dividend equivalents thereon). F4 · price: Under the terms of the settlement of the stock appreciation rights the 20-day average of the closing prices of Pfizer common stock ending on the settlement date is used. Read SEC document |
| February 28, 2020 Filed Mar 3, 2020 17:55 UTC |
YOUNG JOHN DGroup President
|
Tax withholdingCommon Stock | 23,802 | $33.42 | $795,462.84 |
DisclosureSEC source: 0001225208-20-004028 · doc4.xml · nonDerivative · entry 2 YOUNG JOHN D · CIK 0001551792 · Group President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 480,625 F2 · shares: The reported transaction constitutes the withholding of shares to satisfy tax obligations in connection with earn-out of stock appreciation rights. Read SEC document |
| February 28, 2020 Filed Mar 3, 2020 17:55 UTC |
YOUNG JOHN DGroup President
|
Exercise / conversionCommon Stock | 100,548 | $27.37 | $2,751,998.76 |
DisclosureSEC source: 0001225208-20-004028 · doc4.xml · nonDerivative · entry 1 YOUNG JOHN D · CIK 0001551792 · Group President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 504,427 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The reported transaction constitutes the earn-out of stock appreciation rights (including dividend equivalents thereon). Read SEC document |
| February 28, 2020 Filed Mar 3, 2020 17:55 UTC |
SUSMAN SALLYExecutive Vice President
|
Exercise / conversionStock Appreciation Rights · Derivative | 91,408 | $0.00 Strike: $27.37 | $0.00 |
DisclosureSEC source: 0001225208-20-004027 · doc4.xml · derivative · entry 5 SUSMAN SALLY · CIK 0001263544 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 91,408 shares Expires 2020-02-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 28, 2020 Filed Mar 3, 2020 17:55 UTC |
SUSMAN SALLYExecutive Vice President
|
Tax withholdingCommon Stock | 47,221 | $36.45 | $1,721,205.45 |
DisclosureSEC source: 0001225208-20-004027 · doc4.xml · nonDerivative · entry 3 SUSMAN SALLY · CIK 0001263544 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 151,758 F3 · shares: The reported transaction constitutes the withholding of shares to cover payment of exercise price in connection with earn-out of stock appreciation rights (including dividend equivalents thereon). F4 · price: Under the terms of the settlement of the stock appreciation rights the 20-day average of the closing prices of Pfizer common stock ending on the settlement date is used. Read SEC document |
| February 28, 2020 Filed Mar 3, 2020 17:55 UTC |
SUSMAN SALLYExecutive Vice President
|
Tax withholdingCommon Stock | 23,517 | $33.42 | $785,938.14 |
DisclosureSEC source: 0001225208-20-004027 · doc4.xml · nonDerivative · entry 2 SUSMAN SALLY · CIK 0001263544 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 198,979 F2 · shares: The reported transaction constitutes the withholding of shares to satisfy tax obligations in connection with earn-out of stock appreciation rights. Read SEC document |
| February 28, 2020 Filed Mar 3, 2020 17:55 UTC |
SUSMAN SALLYExecutive Vice President
|
Exercise / conversionCommon Stock | 91,408 | $27.37 | $2,501,836.96 |
DisclosureSEC source: 0001225208-20-004027 · doc4.xml · nonDerivative · entry 1 SUSMAN SALLY · CIK 0001263544 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 222,496 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The reported transaction constitutes the earn-out of stock appreciation rights (including dividend equivalents thereon). Read SEC document |
| February 27, 2020 Filed Feb 29, 2020 00:16 UTC |
BOURLA ALBERTDirector · Chairman & CEO
|
GrantStock Appreciation Rights · Derivative | 474,398 | $0.00 Strike: $34.10 | $0.00 |
DisclosureSEC source: 0001225208-20-003783 · doc4.xml · derivative · entry 8 BOURLA ALBERT · CIK 0001595703 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 474,398 Underlying: Common Stock · 474,398 shares Expires 2027-02-27 F9 · derivative.exercise_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant. F9 · derivative.expiration_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant. Read SEC document |
| February 27, 2020 Filed Feb 29, 2020 00:16 UTC |
BOURLA ALBERTDirector · Chairman & CEO
|
GrantStock Appreciation Rights · Derivative | 553,697 | $0.00 Strike: $34.10 | $0.00 |
DisclosureSEC source: 0001225208-20-003783 · doc4.xml · derivative · entry 7 BOURLA ALBERT · CIK 0001595703 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 553,697 Underlying: Common Stock · 553,697 shares Expires 2025-02-27 F8 · derivative.exercise_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant. F8 · derivative.expiration_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant. Read SEC document |
| February 27, 2020 Filed Feb 29, 2020 00:17 UTC |
Dolsten MikaelPresident R&D
|
GrantStock Appreciation Rights · Derivative | 182,461 | $0.00 Strike: $34.10 | $0.00 |
DisclosureSEC source: 0001225208-20-003784 · doc4.xml · derivative · entry 6 Dolsten Mikael · CIK 0001437590 · President R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 182,461 Underlying: Common Stock · 182,461 shares Expires 2027-02-27 F5 · derivative.exercise_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant. F5 · derivative.expiration_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant. Read SEC document |
| February 27, 2020 Filed Feb 29, 2020 00:17 UTC |
Dolsten MikaelPresident R&D
|
GrantStock Appreciation Rights · Derivative | 212,961 | $0.00 Strike: $34.10 | $0.00 |
DisclosureSEC source: 0001225208-20-003784 · doc4.xml · derivative · entry 5 Dolsten Mikael · CIK 0001437590 · President R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 212,961 Underlying: Common Stock · 212,961 shares Expires 2025-02-27 F4 · derivative.exercise_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant. F4 · derivative.expiration_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant. Read SEC document |
| February 27, 2020 Filed Feb 29, 2020 00:19 UTC |
DAMELIO FRANK AExecutive Vice President
|
GrantStock Appreciation Rights · Derivative | 218,953 | $0.00 Strike: $34.10 | $0.00 |
DisclosureSEC source: 0001225208-20-003785 · doc4.xml · derivative · entry 8 DAMELIO FRANK A · CIK 0001194004 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 218,953 Underlying: Common Stock · 218,953 shares Expires 2027-02-27 F8 · derivative.exercise_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant. F8 · derivative.expiration_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant. Read SEC document |
| February 27, 2020 Filed Feb 29, 2020 00:19 UTC |
DAMELIO FRANK AExecutive Vice President
|
GrantStock Appreciation Rights · Derivative | 255,553 | $0.00 Strike: $34.10 | $0.00 |
DisclosureSEC source: 0001225208-20-003785 · doc4.xml · derivative · entry 7 DAMELIO FRANK A · CIK 0001194004 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 255,553 Underlying: Common Stock · 255,553 shares Expires 2025-02-27 F7 · derivative.exercise_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant. F7 · derivative.expiration_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant. Read SEC document |
| February 27, 2020 Filed Feb 29, 2020 00:19 UTC |
Fonseca LidiaExecutive Vice President
|
GrantStock Appreciation Rights · Derivative | 59,117 | $0.00 Strike: $34.10 | $0.00 |
DisclosureSEC source: 0001225208-20-003786 · doc4.xml · derivative · entry 2 Fonseca Lidia · CIK 0001454944 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,117 Underlying: Common Stock · 59,117 shares Expires 2027-02-27 F2 · derivative.exercise_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant. F2 · derivative.expiration_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant. Read SEC document |
| February 27, 2020 Filed Feb 29, 2020 00:19 UTC |
Fonseca LidiaExecutive Vice President
|
GrantStock Appreciation Rights · Derivative | 68,999 | $0.00 Strike: $34.10 | $0.00 |
DisclosureSEC source: 0001225208-20-003786 · doc4.xml · derivative · entry 1 Fonseca Lidia · CIK 0001454944 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 68,999 Underlying: Common Stock · 68,999 shares Expires 2025-02-27 F1 · derivative.exercise_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant. F1 · derivative.expiration_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant. Read SEC document |
| February 27, 2020 Filed Feb 29, 2020 00:22 UTC |
Hwang AngelaGroup President
|
GrantStock Appreciation Rights · Derivative | 145,969 | $0.00 Strike: $34.10 | $0.00 |
DisclosureSEC source: 0001225208-20-003799 · doc4.xml · derivative · entry 9 Hwang Angela · CIK 0001725474 · Group President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 145,969 Underlying: Common Stock · 145,969 shares Expires 2027-02-27 F10 · derivative.exercise_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant. F10 · derivative.expiration_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant. Read SEC document |
| February 27, 2020 Filed Feb 29, 2020 00:22 UTC |
Hwang AngelaGroup President
|
GrantStock Appreciation Rights · Derivative | 170,368 | $0.00 Strike: $34.10 | $0.00 |
DisclosureSEC source: 0001225208-20-003799 · doc4.xml · derivative · entry 8 Hwang Angela · CIK 0001725474 · Group President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 170,368 Underlying: Common Stock · 170,368 shares Expires 2025-02-27 F9 · derivative.exercise_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant. F9 · derivative.expiration_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant. Read SEC document |
| February 27, 2020 Filed Feb 29, 2020 00:24 UTC |
JOHNSON RADY AExecutive Vice President
|
GrantStock Appreciation Rights · Derivative | 39,412 | $0.00 Strike: $34.10 | $0.00 |
DisclosureSEC source: 0001225208-20-003800 · doc4.xml · derivative · entry 9 JOHNSON RADY A · CIK 0001594762 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,412 Underlying: Common Stock · 39,412 shares Expires 2027-02-27 F8 · derivative.exercise_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant. F8 · derivative.expiration_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant. Read SEC document |
| February 27, 2020 Filed Feb 29, 2020 00:24 UTC |
JOHNSON RADY AExecutive Vice President
|
GrantStock Appreciation Rights · Derivative | 45,999 | $0.00 Strike: $34.10 | $0.00 |
DisclosureSEC source: 0001225208-20-003800 · doc4.xml · derivative · entry 8 JOHNSON RADY A · CIK 0001594762 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,999 Underlying: Common Stock · 45,999 shares Expires 2025-02-27 F7 · derivative.exercise_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant. F7 · derivative.expiration_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant. Read SEC document |
| February 27, 2020 Filed Feb 29, 2020 00:25 UTC |
LANKLER DOUGLAS MExecutive Vice President
|
GrantStock Appreciation Rights · Derivative | 127,722 | $0.00 Strike: $34.10 | $0.00 |
DisclosureSEC source: 0001225208-20-003801 · doc4.xml · derivative · entry 9 LANKLER DOUGLAS M · CIK 0001488270 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 127,722 Underlying: Common Stock · 127,722 shares Expires 2027-02-27 F8 · derivative.exercise_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant. F8 · derivative.expiration_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant. Read SEC document |
| February 27, 2020 Filed Feb 29, 2020 00:25 UTC |
LANKLER DOUGLAS MExecutive Vice President
|
GrantStock Appreciation Rights · Derivative | 149,072 | $0.00 Strike: $34.10 | $0.00 |
DisclosureSEC source: 0001225208-20-003801 · doc4.xml · derivative · entry 8 LANKLER DOUGLAS M · CIK 0001488270 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 149,072 Underlying: Common Stock · 149,072 shares Expires 2025-02-27 F7 · derivative.exercise_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant. F7 · derivative.expiration_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant. Read SEC document |
| February 27, 2020 Filed Feb 29, 2020 00:28 UTC |
ROGERS DAWNExecutive Vice President
|
GrantStock Appreciation Rights · Derivative | 59,117 | $0.00 Strike: $34.10 | $0.00 |
DisclosureSEC source: 0001225208-20-003802 · doc4.xml · derivative · entry 8 ROGERS DAWN · CIK 0001742308 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,117 Underlying: Common Stock · 59,117 shares Expires 2027-02-27 F9 · derivative.exercise_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant. F9 · derivative.expiration_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant. Read SEC document |
| February 27, 2020 Filed Feb 29, 2020 00:28 UTC |
ROGERS DAWNExecutive Vice President
|
GrantStock Appreciation Rights · Derivative | 68,999 | $0.00 Strike: $34.10 | $0.00 |
DisclosureSEC source: 0001225208-20-003802 · doc4.xml · derivative · entry 7 ROGERS DAWN · CIK 0001742308 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 68,999 Underlying: Common Stock · 68,999 shares Expires 2025-02-27 F8 · derivative.exercise_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant. F8 · derivative.expiration_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant. Read SEC document |
| February 27, 2020 Filed Feb 29, 2020 00:28 UTC |
SUSMAN SALLYExecutive Vice President
|
GrantStock Appreciation Rights · Derivative | 69,335 | $0.00 Strike: $34.10 | $0.00 |
DisclosureSEC source: 0001225208-20-003803 · doc4.xml · derivative · entry 9 SUSMAN SALLY · CIK 0001263544 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,335 Underlying: Common Stock · 69,335 shares Expires 2027-02-27 F8 · derivative.exercise_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant. F8 · derivative.expiration_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant. Read SEC document |
| February 27, 2020 Filed Feb 29, 2020 00:28 UTC |
SUSMAN SALLYExecutive Vice President
|
GrantStock Appreciation Rights · Derivative | 80,925 | $0.00 Strike: $34.10 | $0.00 |
DisclosureSEC source: 0001225208-20-003803 · doc4.xml · derivative · entry 8 SUSMAN SALLY · CIK 0001263544 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,925 Underlying: Common Stock · 80,925 shares Expires 2025-02-27 F7 · derivative.exercise_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant. F7 · derivative.expiration_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant. Read SEC document |
| February 27, 2020 Filed Feb 29, 2020 00:32 UTC |
YOUNG JOHN DGroup President
|
GrantStock Appreciation Rights · Derivative | 145,969 | $0.00 Strike: $34.10 | $0.00 |
DisclosureSEC source: 0001225208-20-003804 · doc4.xml · derivative · entry 10 YOUNG JOHN D · CIK 0001551792 · Group President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 145,969 Underlying: Common Stock · 145,969 shares Expires 2027-02-27 F8 · derivative.exercise_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant. F8 · derivative.expiration_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant. Read SEC document |
| February 27, 2020 Filed Feb 29, 2020 00:32 UTC |
YOUNG JOHN DGroup President
|
GrantStock Appreciation Rights · Derivative | 170,368 | $0.00 Strike: $34.10 | $0.00 |
DisclosureSEC source: 0001225208-20-003804 · doc4.xml · derivative · entry 9 YOUNG JOHN D · CIK 0001551792 · Group President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 170,368 Underlying: Common Stock · 170,368 shares Expires 2025-02-27 F7 · derivative.exercise_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant. F7 · derivative.expiration_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant. Read SEC document |
| February 27, 2020 Filed Feb 29, 2020 00:34 UTC |
MACKENZIE ALEXANDER RExecutive Vice President
|
GrantStock Appreciation Rights · Derivative | 87,581 | $0.00 Strike: $34.10 | $0.00 |
DisclosureSEC source: 0001225208-20-003805 · doc4.xml · derivative · entry 7 MACKENZIE ALEXANDER R · CIK 0001678459 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,581 Underlying: Common Stock · 87,581 shares Expires 2027-02-27 F4 · derivative.exercise_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant. F4 · derivative.expiration_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant. Read SEC document |
| February 27, 2020 Filed Feb 29, 2020 00:34 UTC |
MACKENZIE ALEXANDER RExecutive Vice President
|
GrantStock Appreciation Rights · Derivative | 102,221 | $0.00 Strike: $34.10 | $0.00 |
DisclosureSEC source: 0001225208-20-003805 · doc4.xml · derivative · entry 6 MACKENZIE ALEXANDER R · CIK 0001678459 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 102,221 Underlying: Common Stock · 102,221 shares Expires 2025-02-27 F3 · derivative.exercise_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant. F3 · derivative.expiration_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant. Read SEC document |
| February 27, 2020 Filed Mar 2, 2020 20:45 UTC |
Quincey JamesDirector
|
GrantPhantom Stock Units · Derivative | 868.49 | $34.10 | $29,615.51 |
DisclosureSEC source: 0001225208-20-003860 · doc4.xml · derivative · entry 1 Quincey James · CIK 0001561264 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 868.49 Underlying: Common Stock · 868.49 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units represent deferred director's compensation that are settled in cash or common stock at the director's election, following the reporting person's retirement from the Board of Directors. F2 · derivative.expiration_date: These units represent deferred director's compensation that are settled in cash or common stock at the director's election, following the reporting person's retirement from the Board of Directors. Read SEC document |
| February 26, 2020 Filed Feb 29, 2020 00:15 UTC |
CANGIALOSI LORETTA VSr. Vice President, Controller
|
Exercise / conversionStock Appreciation Rights · Derivative | 24,155 | $0.00 Strike: $34.59 | $0.00 |
DisclosureSEC source: 0001225208-20-003782 · doc4.xml · derivative · entry 7 CANGIALOSI LORETTA V · CIK 0001174449 · Sr. Vice President, Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 24,155 shares Expires 2020-02-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 26, 2020 Filed Feb 29, 2020 00:15 UTC |
CANGIALOSI LORETTA VSr. Vice President, Controller
|
Tax withholdingCommon Stock | 18,438 | $36.80 | $678,518.40 |
DisclosureSEC source: 0001225208-20-003782 · doc4.xml · nonDerivative · entry 5 CANGIALOSI LORETTA V · CIK 0001174449 · Sr. Vice President, Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 113,322 F5 · shares: The reported transaction constitutes the withholding of shares to cover payment of exercise price in connection with earn-out of stock appreciation rights (including dividend equivalents thereon). F6 · price: Under the terms of the settlement of the stock appreciation rights the 20-day average of the closing prices of Pfizer common stock ending on the settlement date is used. Read SEC document |
| February 26, 2020 Filed Feb 29, 2020 00:15 UTC |
CANGIALOSI LORETTA VSr. Vice President, Controller
|
Tax withholdingCommon Stock | 1,943 | $34.72 | $67,460.96 |
DisclosureSEC source: 0001225208-20-003782 · doc4.xml · nonDerivative · entry 4 CANGIALOSI LORETTA V · CIK 0001174449 · Sr. Vice President, Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 131,760 F4 · shares: The reported transaction constitutes the withholding of shares to satisfy tax obligations in connection with earn-out of stock appreciation rights. Read SEC document |
| February 26, 2020 Filed Feb 29, 2020 00:15 UTC |
CANGIALOSI LORETTA VSr. Vice President, Controller
|
Tax withholdingCommon Stock | 1,290 | $34.72 | $44,788.80 |
DisclosureSEC source: 0001225208-20-003782 · doc4.xml · nonDerivative · entry 3 CANGIALOSI LORETTA V · CIK 0001174449 · Sr. Vice President, Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 133,703 F3 · shares: The reported transaction constitutes the withholding of shares to satisfy tax obligations upon the earn-out of Performance Share Awards (including dividend equivalents thereon). Read SEC document |
| February 26, 2020 Filed Feb 29, 2020 00:15 UTC |
CANGIALOSI LORETTA VSr. Vice President, Controller
|
GrantCommon Stock | 3,797 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-20-003782 · doc4.xml · nonDerivative · entry 2 CANGIALOSI LORETTA V · CIK 0001174449 · Sr. Vice President, Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 134,993 F2 · shares: The reported transaction constitutes the earn-out of Performance Share Awards (including dividend equivalents thereon). Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.